Glenmark Pharmaceuticals Opens Monoclonal Antibody Manufacturing Facility - - BioPharm International

ADVERTISEMENT

Glenmark Pharmaceuticals Opens Monoclonal Antibody Manufacturing Facility


Glenmark Pharmaceuticals, India, has opened a new cGMP-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.

Glenmark Pharmaceuticals' Swiss research center has in-house capabilities and infrastructure for conducting antibody discovery, cell-line development, in-vitro testing and characterization of antibodies, process development, and analytical research. The new manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade material. The manufacturing facility has been designed for use of single-use bioreactor systems and also houses a suite for manufacturing cell banks.

Source: Glenmark Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here